Loading clinical trials...

Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT06529796

Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment

The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of Inaxaplin (IXP) in participants with mild or moderate hepatic impairment and in matched healthy participants.

Lead sponsor: Vertex Pharmaceuticals Incorporated•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITINGNA

SLIT ABS: Study on Patients With Autoimmune Podocytopathy

NCT07516964 · Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, and more

TERMINATEDPhase 2

A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

NCT03448692 · Focal Segmental Glomerulosclerosis (FSGS)

COMPLETEDPhase 1

A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

NCT05955872 · Focal Segmental Glomerulosclerosis (FSGS)

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 20, 2025Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment36

Start dateAug 2024

Last updatedJan 20, 2025

Condition

Focal Segmental Glomerulosclerosis (FSGS)

Locations shown

Division of Clinical Pharmacology, University of Miami

Miami, Florida

GCP Research

St. Petersburg, Florida

Texas Liver Institute

San Antonio, Texas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 20, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions